Splash Wave 3.jpg

Clinical Trial

Splash Pharmaceuticals is now conducting an open-label Phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.  

For more information, please see:

https://clinicaltrials.gov/ct2/show/NCT03078400?term=spl-108&rank=1